ClinicalTrials.gg
RecruitingNCT07287891VERTIGOUpdated Dec 17, 2025

Lost in the Labyrinth: Predicting Central Neurological Causes of Vertigo Dizziness and Unsteadiness in the Emergency Department. A Multicentre Cross-sectional Observational Study

An observational study in ED With Vertigo, Dizziness and Unsteadiness, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
825
Ages
18 Years and older
Sex
All
01

Study summary

This study will assess the sensitivity and specificity of the bedside examination algorithm performed by ED physicians. Finally, it aims to identify predictors of a central cause of the symptoms. This will consequently reduce the rate of misdiagnosis as well as the costs and length of stay due to inappropriate neuroimaging.

02

Conditions studied

  • ED With Vertigo
  • Dizziness
  • Unsteadiness

Browse trials for

03

In context

Dizziness

226 studies on the registry are indexed under Dizziness; 56 are open to participants now.

This study's planned enrollment of 825 is above the median of 126 across 44 observational studies indexed under Dizziness.

Browse Dizziness studies →

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 257 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting at the ED with vertigo, dizziness or unsteadiness

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting at the ED with vertigo, dizziness or unsteadiness
  • >= 18 years of age
  • Patients able to give their consent

Exclusion criteria

Exclusion Criteria:

  • Patients with dementia
  • Bedridden patients (for causes other than the current symptoms)
  • Patients with obvious neurological findings presenting with vertigo but with suspected stroke at triage
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
825 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients presenting at the ED with vertigo, dizziness, and unsteadiness

    Patients presenting to the ED with vertigo/ dizziness

    Diagnostic Test: Bedside examination of Vertigo

Interventions

  • Diagnostic testBedside examination of Vertigo

    ED visit comprehensive of bedside examination of vertigo performed by trained EP or emergency medicine residents

06

What researchers measure

Primary outcomes

  1. The AUC of the bedside examination algorithm performed by ED physicians

    Time frame: up to 36 months

Secondary outcomes

  1. identification of predictors of true positive patients

    Predictors of true positive patients can help to stratify patients with vertigo for the risk of stroke.

    Time frame: up to 36 months

  2. evaluation of number of neuroimaging tests (TC and angio-TC) performed to patients with vertigo in the ED.tests performed

    to study the use of ED resources for these patients in terms of number of neuroimaging tests performed.

    Time frame: up to 36 months

07

Study locations

1 of 1 sites recruiting
  • SC Pronto Soccorso e Medicina d'Urgenza, Fondazione IRCCS Policlinico San Matteo
    Pavia, Pavia 27100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Jan 26, 2024
Primary completionEst.
Feb 26, 2027
CompletionEst.
Feb 26, 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07287891
Responsible party
Marco Bonzano (MD, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Dec 17, 2025
Start date
Jan 26, 2024
Primary completion
Feb 26, 2027 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

Marco Bonzano, MD
Contact
m.bonzano@smatteo.pv.it
+390382502039

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion